The Proceedings of the 14th International Conference on Myasthenia Gravis and Myasthenic Disorders cover various facets of myasthenia gravis (MG), including immunological research, treatment modalities, and outcomes of clinical trials. Highlights include studies on antibody mutation in germinal centers and the immunopathology of MG, alongside trials investigating corticosteroid-sparing treatments such as methotrexate and cyclosporine, and the effectiveness of immunoglobulins and newer therapies in severe MG cases. Pediatric MG is notably discussed, with an emphasis on its clinical symptoms, treatment approaches, and generally better prognosis than in adults, with a particular focus on the benefits of early thymectomy. The section on pediatric MG delves into the diagnosis and management of the disease in young patients, presenting a comprehensive treatment framework that combines drug therapies and non-pharmacological methods. Recommended strategies include early thymectomy for improved outcomes and tailored use of medications like pyridostigmine and corticosteroids to minimize side effects. The importance of immunoglobulins and plasma exchange for tough cases is also covered. The text underscores the necessity of a multidisciplinary approach involving various specialists to enhance treatment efficacy and manage the overall impact of MG on children’s lives, aiming for remission and optimal quality of life.

Reference: Proceedings of the MGFA International Conference. RRNMF Neuromuscular J. 2023 Aug 29;4(3). doi: 10.17161/rrnmf.v4i3.